Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Telix Pharmaceuticals ( (AU:TLX) ) has shared an update.
Telix Pharmaceuticals has announced a change in the director’s interest, specifically for Dr. Christian Behrenbruch, who has acquired 166,483 Performance Share Appreciation Rights (PSARs) and 2,595 Deferred Share Rights (SRs) as part of his remuneration package. This change reflects the company’s commitment to aligning executive compensation with performance goals, potentially impacting the company’s operational focus and stakeholder interests by incentivizing leadership to achieve significant revenue milestones.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited operates in the biotechnology industry, focusing on the development of diagnostic and therapeutic products using molecularly targeted radiation. The company primarily targets the oncology market, aiming to improve cancer diagnosis and treatment through innovative radiopharmaceuticals.
Average Trading Volume: 1,600,992
Technical Sentiment Signal: Buy
Current Market Cap: A$8.66B
See more data about TLX stock on TipRanks’ Stock Analysis page.